Vesugen Peptide Research – Complete Guide

Table of Contents

• Quick Facts
• What is Vesugen?
• Molecular Structure and Core Properties
• Mechanisms of Action Being Investigated
• Major Areas of Research
• Pharmacokinetics and Biological Distribution
• Research Limitations and Evidence Gaps
• Regulatory and Research Status
• Key Research Findings
• Frequently Asked Questions
• References

Quick Facts (Research Snapshot)

• Primary Research Areas: Vascular aging, endothelial function, epigenetic gene regulation, neuroprotection, geroprotection
• First Developed: Saint Petersburg Institute of Bioregulation and Gerontology, Russia; part of Vladimir Khavinson’s peptide bioregulator research program
• Amino Acid Sequence: Lysine-Glutamic Acid-Aspartic Acid (Lys-Glu-Asp)
• Molecular Weight: Sub-1 kDa range (consistent with tripeptide classification)
• Research Status: Preclinical studies predominate; limited small-scale clinical data from Russian Federation; no Western replication studies identified
• Key Mechanisms: MKI67 gene promoter binding, SIRT1 activation, endothelin-1 normalization, VEGF restoration, nitric oxide upregulation
• Published Studies: Primarily Russian-origin publications; limited PubMed-indexed English-language literature
• Clinical Trial Status: No Phase II or Phase III trials identified; four small observational studies from Russia
• Regulatory Classification: Research use only; not approved for human therapeutic use in any major jurisdiction

What is Vesugen?

Vesugen is a synthetic tripeptide bioregulator composed of three amino acids: lysine, glutamic acid, and aspartic acid, abbreviated as KED from the single-letter codes of its constituent residues. It was developed at the Saint Petersburg Institute of Bioregulation and Gerontology as part of an extensive research program led by Vladimir Khavinson, whose group spent decades investigating short-chain peptides capable of modulating gene expression and protecting cellular function during aging.

The compound belongs to a class of molecules called peptide bioregulators, which are short synthetic peptides derived from or inspired by polypeptide complexes originally extracted from animal tissues. In Vesugen’s case, the research lineage traces to polypeptide fractions isolated from cattle blood vessels. The synthetic tripeptide was developed to replicate and investigate the biological activity of those natural vascular-tissue extracts in a reproducible, precisely characterized form suitable for controlled research.

Researchers became interested in Vesugen because of its proposed ability to act at the gene level rather than simply binding cell-surface receptors. Unlike most peptide drugs that interact with membrane proteins, Vesugen appears to enter cells and interact directly with DNA promoter sequences, placing it in a mechanistically unusual category for a small peptide. This epigenetic activity, combined with its vascular origin and observed effects on aging markers in animal models, made it a candidate for studying age-related vascular decline.

Most published research on Vesugen comes from Russian institutional sources, with studies conducted at the Khavinson laboratory and associated institutes. The research covers three overlapping domains: vascular and endothelial biology, neuroprotection, and general geroprotection. While preclinical findings across cell culture and aged rodent models are detailed, global validation through independent Western replication studies has not been published. All available clinical data derives from small Russian observational studies without the placebo-controlled trial designs required by major regulatory agencies. Vesugen remains classified for research use only.

A note on nomenclature: some commercial sources and occasional publications describe Vesugen as a tetrapeptide. The preponderance of evidence from the primary research literature confirms it as a tripeptide containing three amino acid residues (Lys-Glu-Asp). The variant spelling "Vezugen" also appears in some sources and refers to the same compound.

Molecular Structure and Core Properties

Chemical Structure and Specifications

Key Structural Features

Vesugen’s three-residue structure places it in the smallest category of biologically active peptides. Lysine contributes a positively charged side chain at physiological pH, glutamic acid provides a negatively charged carboxylate group, and aspartic acid adds a second acidic residue. This combination of charge states across three adjacent amino acids creates a molecule capable of forming hydrogen bonds with nucleic acid structures, which researchers hypothesize underlies Vesugen’s proposed DNA promoter interactions.

The tripeptide’s small molecular size is significant for its proposed mechanism. Molecules below approximately 500 daltons cross cell membranes more readily than larger peptides, and at roughly 351 g/mol Vesugen falls well within this range. Khavinson’s research group has proposed that this membrane permeability enables Vesugen to reach nuclear DNA directly, distinguishing it mechanistically from receptor-binding peptides that act at the cell surface.

Stability under physiological conditions presents a recognized challenge for tripeptides generally. Without protective modifications such as PEGylation or cyclization, short-chain peptides are susceptible to rapid degradation by plasma and tissue peptidases. Research protocols account for this by investigating both oral and injectable routes, though detailed pharmacokinetic data specific to Vesugen remains limited in the published literature.

Mechanisms of Action Being Investigated

Vesugen’s proposed biological activity involves several distinct pathways, spanning epigenetic gene regulation, vascular signaling, metabolic longevity pathways, and direct neuronal support. These mechanisms emerge from different experimental models and should be understood as research findings rather than established clinical pharmacology.

MKI67 Gene Promoter Binding and Epigenetic Regulation

The most structurally specific mechanism attributed to Vesugen is direct binding to the promoter region of the MKI67 gene. Studies in the Khavinson laboratory demonstrated that the KED tripeptide interacts with the MKI67 promoter at positions -14 to +12 base pairs relative to the transcription start site [1].

MKI67 encodes the Ki-67 protein, a nuclear protein that serves as a well-established marker of active cell proliferation. Ki-67 expression declines with aging in many tissue types, and reduced endothelial cell renewal is a recognized feature of vascular aging. By binding to the MKI67 promoter region, Vesugen is proposed to enhance gene transcription and thereby stimulate Ki-67 expression, promoting endothelial cell renewal in aging tissue [2].

The proposed binding mechanism involves minor groove hydrogen bond interactions between the peptide’s charged residues and the DNA double helix. This interaction is sequence-specific to the MKI67 promoter region, which the researchers describe as explaining Vesugen’s targeted vascular effects. This proposed epigenetic activity is the basis for classifying Vesugen as an "epigenetic vascular bioregulator" rather than a conventional receptor-targeted peptide drug.

Endothelin-1 Normalization and Anti-Atherosclerotic Signaling

Vesugen modulates endothelin-1, a potent vasoconstrictor peptide produced by endothelial cells. Endothelin-1 levels are elevated in atherosclerosis, contributing to sustained vasoconstriction and vascular wall inflammation that accelerates plaque development. Cell culture studies using aortic endothelial cells from atherosclerosis patients showed reduced endothelin-1 levels following Vesugen treatment [3].

Normalized endothelin-1 is proposed to reduce atherosclerotic and restenotic processes by relieving chronic vasoconstriction and reducing endothelial inflammatory signaling. This pathway complements Vesugen’s nitric oxide effects, described below, by acting on both constrictor and dilator arms of vascular tone regulation.

VEGF Restoration in Vascular and Neurological Models

Vascular endothelial growth factor (VEGF) supports blood vessel maintenance, endothelial cell survival, and angiogenesis. Studies report that Vesugen restores VEGF levels in aortic endothelial cells from atherosclerosis patients and contributes to VEGF recovery in experimental Alzheimer’s disease models following oral KED administration [4].

VEGF reduction in aging vasculature impairs the maintenance and repair capacity of blood vessel walls. Restoring VEGF signaling in aged or diseased endothelial cells is therefore a plausible mechanism through which Vesugen could support vascular integrity during aging, though the upstream driver of this VEGF restoration has not been fully characterized in the available literature.

Nitric Oxide Production Enhancement

Animal studies in aged Wistar rats demonstrated increased nitric oxide production following Vesugen administration [5]. Nitric oxide is a gaseous signaling molecule produced by endothelial cells that promotes vascular smooth muscle relaxation, inhibits platelet aggregation, and reduces endothelial inflammation. Nitric oxide bioavailability declines with aging, contributing to age-related increases in vascular stiffness and blood pressure.

Improved nitric oxide production in aged animal models translated to observed improvements in endothelial cell morphology and microcirculation, suggesting functional vascular effects downstream of the molecular signal. Whether this nitric oxide enhancement derives from Vesugen’s gene regulatory activity or from direct enzymatic effects on nitric oxide synthase has not been clarified.

SIRT1 Activation and Metabolic Longevity Signaling

Vesugen appears to activate sirtuin 1 (SIRT1), a NAD-dependent deacetylase central to metabolic regulation, insulin sensitivity, and cellular longevity signaling [6]. Mouse model studies linked Vesugen administration to SIRT1-associated improvements in insulin resistance, with researchers proposing that the compound produces metabolic effects similar to calorie restriction, a recognized longevity intervention, without requiring dietary changes.

SIRT1 activation connects Vesugen’s vascular research application to broader metabolic and longevity biology. The pathway is relevant to type 2 diabetes research because SIRT1 deacetylates multiple targets that regulate glucose metabolism and insulin signaling. Whether Vesugen activates SIRT1 directly or through downstream effects of its gene regulatory activity remains an open research question.

Telomerase Upregulation and Anti-Apoptotic Gene Expression

Studies attribute to Vesugen an upregulation of telomerase activity and anti-apoptotic gene expression in experimental models [7]. Telomerase maintains telomere length by adding repetitive DNA sequences to chromosome ends, counteracting the telomere shortening that accumulates with each cell division and contributes to cellular senescence. Upregulating telomerase activity is a recognized strategy in anti-aging research for extending the replicative lifespan of cells.

Alongside telomerase effects, Vesugen administration has been associated with modulated expression of p16 and p21, two cyclin-dependent kinase inhibitors that drive cells into senescence or apoptosis when activated. Reducing inappropriate p16 and p21 signaling in aged cells is proposed as a mechanism for reducing the accumulation of senescent cells that impairs tissue function during aging.

Neuroprotective Mechanisms: Synaptic and Structural Effects

Vesugen shows activity in neurological cell models that researchers interpret as neuroprotective. In Alzheimer’s disease cell culture models, Vesugen treatment restored synaptic plasticity and improved neuron survival under amyloid-induced stress [8]. In Huntington’s disease cell models, spine density increased by up to 32% with Vesugen treatment, with mushroom-type spine density also increasing approximately 1.2-fold in amyloid synaptotoxicity models [9].

Dendritic spines are the primary sites of excitatory synaptic contact in neurons. Spine density and morphology directly correlate with synaptic transmission efficiency and cognitive function. Their reduction is a hallmark of Alzheimer’s, Huntington’s, and other neurodegenerative conditions. Vesugen’s capacity to increase spine density in these models suggests it may support synaptic structural integrity, though this has not been replicated outside the originating research group.

Vesugen also stimulates neuronal differentiation in human dental pulp stem cells and promotes dendritic arborization in neuronal models, suggesting broader effects on neuronal growth and structural development beyond its vascular applications [10].

Major Areas of Research

Vesugen research spans three overlapping domains: vascular biology and aging, neurological protection, and general geroprotection. Each area involves both in vitro and in vivo data, though the volume and methodological quality of evidence varies considerably across domains.

Vascular Aging and Endothelial Function Studies

Vascular aging drives cardiovascular disease risk and contributes to cognitive decline through reduced cerebral blood flow. Endothelial dysfunction, characterized by impaired nitric oxide production, elevated inflammatory signaling, and reduced cell renewal capacity, is a central feature of age-related vascular decline. Vesugen research targets this process directly through its proposed effects on endothelial Ki-67 expression, endothelin-1 levels, and nitric oxide bioavailability.

Cell culture studies using endothelial cells from both young and aged animals showed that Vesugen treatment stimulated endothelial cell renewal through Ki-67 upregulation. Studies using aortic endothelial cells from atherosclerosis patients demonstrated VEGF restoration and endothelin-1 normalization [3,4]. In aged Wistar rat models, Vesugen produced improved endothelial cell morphology, increased nitric oxide production, and enhanced microcirculation [5].

The atherosclerosis clinical study, involving 41 patients with vasculogenic erectile dysfunction secondary to atherosclerosis, reported improved penile artery blood flow following oral Vesugen, providing limited human correlative data for the endothelial effects observed in preclinical models [11].

Key Research Highlights:

• Endothelial cell renewal stimulated in aged animal tissue cultures through Ki-67 pathway
• VEGF restoration and endothelin-1 normalization in atherosclerosis patient endothelial cells
• Improved microcirculation and endothelial morphology in aged Wistar rat models

Cerebrovascular Protection and Ischemia Research

Cerebral ischemia research tests whether Vesugen’s vascular effects translate to protection against stroke-like events in aged animals. In aged Wistar rats subjected to induced cerebral ischemia, Vesugen-treated animals showed reduced infarct size and improved survival rates compared to untreated controls [12].

This finding suggests that Vesugen’s endothelial and nitric oxide effects may provide protective benefits during acute ischemic events, potentially through enhanced collateral blood flow or reduced reperfusion injury. The aged animal model is relevant because age is the primary risk factor for stroke in humans, and age-related vascular dysfunction increases both stroke incidence and severity.

No human ischemia or stroke trial data is available. The aged Wistar rat findings represent a preclinical signal that would require dedicated human safety and efficacy trials before any clinical interpretation.

Key Research Highlights:

• Reduced cerebral infarct size in aged Wistar rat ischemia models
• Improved survival following induced cerebral ischemia in aged animals
• Mechanistic alignment with nitric oxide and endothelial protection pathways

Alzheimer’s Disease and Cognitive Aging Models

Vesugen shows activity across several Alzheimer’s-relevant experimental systems. In cell culture Alzheimer’s models, the compound restored synaptic plasticity and improved neuron survival under amyloid beta-induced stress. In amyloid synaptotoxicity models, mushroom-type spine density increased approximately 1.2-fold, a result relevant because mushroom spines are the most stable synapse-bearing spine type and their loss is associated with memory impairment [8].

In the 5xFAD transgenic mouse model, which expresses five familial Alzheimer’s mutations and develops aggressive amyloid pathology, Vesugen treatment showed a positive trend in restoring long-term potentiation (LTP), a cellular mechanism central to memory formation. The result approached but did not reach statistical significance (p = 0.057), limiting interpretation [9].

Oral KED administration contributed to VEGF recovery in Alzheimer’s experimental models, potentially supporting cerebrovascular integrity through vascular growth factor restoration [4]. The gene expression data shows Vesugen modulates SUMO and APOE expression, both implicated in Alzheimer’s pathogenesis, suggesting multiple potential entry points into disease biology.

Key Research Highlights:

• Restored synaptic plasticity and improved neuron survival in Alzheimer’s cell culture models
• Increased mushroom-type spine density in amyloid synaptotoxicity models
• Positive but non-significant LTP trend in 5xFAD mouse model (p = 0.057)

Huntington’s Disease and Neurodegeneration Models

Huntington’s disease models provide a distinct neurodegeneration context for Vesugen research. Cell culture studies showed a 32% increase in dendritic spine density in HD models following Vesugen treatment [9]. Huntington’s disease involves progressive striatal neuronal loss with early synaptic dysfunction, making spine density a meaningful structural readout of potential neuroprotection.

Vesugen’s modulation of NES (Nestin) and GAP43 gene expression is relevant to this application. Nestin marks neural stem and progenitor cells, and GAP43 is associated with axonal growth and synaptic plasticity. Upregulation of these markers suggests Vesugen may support neuronal growth processes in addition to protecting existing synaptic structures [7].

The Huntington’s data is exclusively from in vitro models. No animal in vivo data or clinical data in HD populations has been identified in the available literature.

Key Research Highlights:

• 32% increase in dendritic spine density in HD cell culture models
• Modulation of NES and GAP43 gene expression relevant to neuronal growth
• All findings limited to cell culture; no animal or human HD data available

Metabolic Health and Insulin Sensitivity Research

SIRT1 activation connects Vesugen to metabolic longevity research. Mouse model studies showed that Vesugen administration improved insulin sensitivity through SIRT1-associated pathways, with researchers proposing a mechanism similar to calorie restriction [6]. This positions Vesugen as a potential tool for studying the intersection of vascular aging and metabolic dysfunction, conditions that frequently co-occur in elderly populations.

Type 2 diabetes significantly accelerates vascular aging and endothelial dysfunction through hyperglycemia-induced oxidative stress and advanced glycation end-products. A compound that addresses both endothelial function and insulin sensitivity through distinct molecular pathways (MKI67 binding plus SIRT1 activation) could have research value in diabetic vascular disease models.

Available data is limited to murine models. The specific dosing, study duration, and insulin sensitivity measurement methods are not detailed in English-language literature summaries.

Key Research Highlights:

• SIRT1-linked improvements in insulin resistance in murine models
• Proposed calorie-restriction-mimetic metabolic effects
• Research intersection of vascular aging and metabolic dysfunction

Geroprotection and Anti-Aging Biology

The broader geroprotective profile of Vesugen spans telomerase activity, anti-apoptotic gene regulation, and senescence marker modulation. Research associates Vesugen with upregulated telomerase activity and reduced expression of p16 and p21, the primary drivers of cellular senescence [7]. Together these effects suggest Vesugen may extend cellular replicative lifespan and reduce senescent cell accumulation in aging tissues.

The clinical study in 32 elderly patients with polymorbidity and organic brain syndrome reported slowed biological aging markers alongside improved CNS and organ function. However, the same study identified prooxidant activity measured by chemiluminescence and inhibition of hematopoiesis through reduced CD34+ stem cell counts, important negative findings that complicate interpretation of the beneficial effects [13].

These mixed clinical signals, along with the absence of placebo-controlled data, mean the geroprotective research currently rests primarily on preclinical mechanistic evidence rather than clinical efficacy demonstration.

Key Research Highlights:

• Telomerase upregulation and anti-apoptotic gene expression enhancement in experimental models
• Modulation of p16 and p21 senescence markers
• Mixed signals in elderly clinical study: beneficial aging markers alongside prooxidant activity and reduced CD34+ stem cells

Pharmacokinetics and Biological Distribution

Absorption and Bioavailability

Oral bioavailability for short-chain tripeptides presents a recognized pharmacokinetic challenge. Small peptides are susceptible to degradation by gastrointestinal peptidases before intestinal absorption can occur, and even absorbed peptides face first-pass hepatic metabolism. No specific bioavailability data for Vesugen has been identified in the available published literature.

Despite this pharmacokinetic consideration, multiple clinical studies and preclinical investigations used oral Vesugen and reported biological effects, suggesting some degree of active compound or biologically active metabolite reaches systemic circulation [11,13]. This could occur through paracellular absorption of intact tripeptide, absorption of degradation products with residual activity, or indirect effects through gastrointestinal receptor interactions that generate systemic signals.

Distribution and Metabolism

Vesugen’s small molecular size (approximately 351 g/mol) theoretically facilitates cell membrane permeability compared to larger peptides. The proposed mechanism of direct nuclear DNA interaction requires intracellular and intranuclear penetration, which the Khavinson research group attributes in part to the compound’s size and charge characteristics [1].

Tissue distribution data from animal studies is not available in the accessible English-language literature. The vascular tropism observed in preclinical research suggests preferential distribution to or activity in endothelial tissues, but whether this reflects active targeting, passive concentration, or local tissue stability differences has not been characterized.

Delivery Methods Under Investigation

• Oral administration: Used in multiple clinical studies and some preclinical protocols; pharmacokinetics challenging for tripeptides but effects observed in research contexts
• Injectable administration: Referenced as a delivery route in research contexts; injection-site irritation has been noted as a potential adverse effect, confirming parenteral administration has been explored
• Research formulation: Sold as a lyophilized research compound requiring reconstitution per standard research protocols

Excretion and Clearance

As a tripeptide without protective modifications, Vesugen is expected to undergo standard peptide degradation pathways through aminopeptidases, carboxypeptidases, and dipeptidyl peptidases in plasma and tissues. Clearance is expected to be relatively rapid, consistent with unprotected short-chain peptide kinetics generally. No specific half-life or clearance data for Vesugen has been published in the accessible research literature.

The disconnect between expected rapid clearance and reported biological effects in aging-related models represents an unresolved pharmacokinetic question. Khavinson’s group has proposed that even brief gene promoter interactions by short-chain peptides can initiate sustained transcriptional changes that outlast the compound’s presence in tissue, a hypothesis that requires independent verification.

Research Limitations and Evidence Gaps

Current Research Gaps

Human Clinical Data

• No randomized, placebo-controlled clinical trials have been conducted for Vesugen in any indication
• All four identified clinical studies are small (n = 41, n = 32, and two with unspecified sample sizes), originate from Russian institutions, and lack the methodological detail required for international replication assessment
• No Phase II or Phase III trials have been initiated or registered in accessible international databases
• One study used Vesugen in combination with Pinealon, making it impossible to isolate Vesugen-specific effects in that cohort [13]
• Long-term safety in humans has not been assessed in any published study

Mechanistic Understanding

• DNA promoter binding evidence comes exclusively from the Khavinson research group without independent replication
• The upstream driver of VEGF restoration has not been characterized mechanistically
• How Vesugen reaches the cell nucleus to interact with the MKI67 promoter has not been directly demonstrated
• Whether SIRT1 activation is a direct or indirect downstream effect remains unresolved
• The 5xFAD Alzheimer’s mouse model LTP result failed to reach statistical significance (p = 0.057), limiting conclusions from the most rigorous animal study identified

Safety Concerns From Available Data

• The elderly polymorbidity study identified prooxidant activity through chemiluminescence measurements, a concerning finding not addressed in subsequent research [13]
• The same study found reduced CD34+ hematopoietic stem cells, suggesting possible inhibition of blood cell production that warrants investigation before human use
• Injection-site irritation has been noted for parenteral administration
• No systematic toxicology study has been published for Vesugen

Methodological Considerations

• No Western or independent replication of any preclinical or clinical finding exists in the accessible literature
• Publication venue limitations restrict peer-review quality assessment for most primary sources
• Oral bioavailability has not been measured, making interpretation of oral route studies uncertain
• Species and strain differences between study models limit cross-study comparisons

Areas Needing Further Investigation

• Independent replication of MKI67 promoter binding in non-originating laboratories: essential for establishing mechanistic credibility
• Systematic oral pharmacokinetics study: necessary to interpret all oral administration findings
• Randomized placebo-controlled trials with pre-specified endpoints: the minimum requirement for clinical evidence
• Full safety and toxicology characterization: including hematopoietic effects, prooxidant potential, and long-term organ function
• Long-term effects beyond short study periods: completely uninvestigated

Regulatory and Research Status

Current Classification

FDA Status Vesugen holds no FDA approval for human therapeutic use and is not recognized as an approved drug or biological product in the United States. It falls into the category of unapproved peptide research compounds. The FDA classifies such compounds as new drugs requiring approval before human administration, making research-context procurement and use the only legally compliant framework in the United States.

International Regulatory Perspective The European Medicines Agency has not approved Vesugen for human use. In Russia, where most clinical research originates, the regulatory pathway differs from Western frameworks, and the small clinical studies conducted there would not satisfy EMA or FDA approval standards. Most major markets classify Vesugen as a research chemical rather than an approved therapeutic.

WADA Status Vesugen does not appear on the current World Anti-Doping Agency prohibited list by name. However, WADA’s prohibited list includes broad categories covering peptide hormones, growth factors, and related substances, and peptides with demonstrated growth factor-related activity may fall under these general categories. Athletes subject to anti-doping regulations should consult applicable guidelines before any use.

Research Community Approach

Legitimate Vesugen research occurs primarily in institutional settings affiliated with the Khavinson bioregulator research tradition in Russia. Western academic institutions have not adopted Vesugen as an active research priority based on available literature. Research use requires standard institutional review board oversight for any study involving human participants, and compliance with applicable institutional biosafety and chemical handling regulations for laboratory work.

The narrow research base, dominated by a single research group and institution, limits the diversity of scientific perspectives applied to Vesugen biology. This represents a structural limitation on the evidence base that independent investigators should consider when evaluating Vesugen research claims.

Future Research Directions

Establishing Vesugen’s research credibility internationally requires independent replication of the MKI67 promoter binding mechanism, systematic pharmacokinetic characterization, and at minimum a well-designed randomized pilot clinical trial with pre-specified safety and biomarker endpoints. The mixed safety signal from the elderly clinical study (prooxidant activity, reduced CD34+ stem cells) warrants dedicated safety investigation before broader clinical research proceeds. Collaboration between Russian and Western research institutions would accelerate the international validation that current evidence lacks.

Key Research Findings

MKI67 Promoter Binding and Ki-67 Expression

Research Focus: Direct gene promoter interaction as the proposed primary mechanism of vascular epigenetic regulation Key Results: Vesugen binds the MKI67 gene promoter at positions -14 to +12 base pairs relative to the transcription start site; stimulates Ki-67 protein expression in endothelial cell cultures from young and aged animals; proposed minor groove hydrogen bond interaction mechanism Significance: Represents the most structurally specific proposed mechanism for any peptide bioregulator in Khavinson’s research program; positions Vesugen as an epigenetic rather than receptor-pharmacological agent Limitations: Evidence comes exclusively from the originating research group; no independent laboratory has published replication of this finding; direct nuclear localization of the tripeptide has not been demonstrated [1,2]

Vascular Effects in Aged Wistar Rat Models

Research Focus: In vivo vascular function in aged animals following Vesugen administration Key Results: Increased nitric oxide production in aged Wistar rats; improved endothelial cell morphology; enhanced microcirculation; reduced infarct size and improved survival following induced cerebral ischemia Significance: Provides in vivo correlate for in vitro endothelial findings; aged animal model is relevant to human vascular aging research; cerebral ischemia protection finding represents the most clinically significant animal result Limitations: Single species studied; no dose-response characterization published in accessible English-language sources; no independent replication identified [5,12]

Atherosclerosis Endothelial Cell Studies

Research Focus: Molecular effects on endothelial cells from atherosclerosis patients Key Results: Restored VEGF levels in aortic endothelial cells; normalized endothelin-1 levels; findings observed in patient-derived rather than healthy tissue, increasing translational relevance Significance: Use of atherosclerosis patient-derived cells rather than healthy or model cells strengthens the preclinical-to-clinical bridge; VEGF and endothelin-1 are established cardiovascular disease biomarkers Limitations: Cell culture data only; patient-derived cells do not replicate in vivo disease environment; number of patient samples not specified in available sources [3,4]

Clinical Study: Vasculogenic Erectile Dysfunction

Research Focus: Oral Vesugen in patients with atherosclerosis-related erectile dysfunction Key Results: Improved penile artery blood flow confirmed by clinical assessment and instrumental measurement in 41 patients Significance: Represents the largest individual clinical study identified; provides human correlate for vascular blood flow effects seen in animal models; atherosclerotic vascular dysfunction is a direct extension of Vesugen’s proposed mechanism Limitations: No control group described in available sources; no placebo arm; Russian institutional origin limits peer-review assessment; effect size and statistical analysis not available in English-language summaries [11]

Elderly Clinical Study: Polymorbidity and Aging Markers

Research Focus: Combination Vesugen and Pinealon treatment in elderly patients with organic brain syndrome Key Results: Anabolic effects observed; improved CNS function and general organ function; slowed biological aging markers. Concerning findings: prooxidant activity by chemiluminescence; inhibited hematopoiesis with reduced CD34+ stem cells; no effect on chromatin condensation Significance: Only study combining positive aging marker effects with concurrent safety concerns; prooxidant and hematopoietic findings represent the most significant adverse signal in the clinical literature Limitations: n = 32 only; combination therapy prevents attribution of effects to Vesugen alone; no placebo control; Russian origin; full methodology unavailable in English-language sources [13]

Neurodegeneration Cell Culture Studies

Research Focus: Synaptic and structural effects in Alzheimer’s and Huntington’s disease models Key Results: Restored synaptic plasticity and improved neuron survival in Alzheimer’s cell models; 32% increase in dendritic spine density in Huntington’s disease models; 1.2-fold increase in mushroom-type spines in amyloid synaptotoxicity models; neuronal differentiation stimulated in human dental pulp stem cells Significance: Spine density increases in HD models represent a quantitative structural finding that is reproducible and meaningful as a biomarker; neuronal differentiation in human stem cells provides a human cell biology correlate Limitations: All in vitro; no animal HD model data; 5xFAD mouse LTP result did not reach significance; findings not independently replicated [8,9,10]

Frequently Asked Questions

What is Vesugen?

Vesugen is a short synthetic peptide composed of three amino acids: lysine, glutamic acid, and aspartic acid, abbreviated KED. It was developed by researchers at the Saint Petersburg Institute of Bioregulation and Gerontology in Russia and is studied for its potential effects on blood vessel health, cellular aging, and neuroprotection in laboratory models.

What does Vesugen research focus on?

Research on Vesugen primarily investigates its effects on aging blood vessels, including how it influences the cells lining blood vessels, nitric oxide production, and markers of vascular health in aged animals. Researchers also study Vesugen in models of Alzheimer’s and Huntington’s disease, and in metabolic models related to aging and insulin sensitivity.

How long has Vesugen been studied?

Vesugen research originates from Vladimir Khavinson’s peptide bioregulator program at the Saint Petersburg Institute of Bioregulation and Gerontology, which has been active for several decades. Most of the accessible published research on Vesugen specifically dates from the 2000s through the 2020s, though the broader peptide bioregulator research tradition it belongs to has roots in earlier Soviet-era pharmacology research.

Is there human clinical data on Vesugen?

A small number of clinical studies from Russia have investigated Vesugen in humans, including a study of 41 patients with vascular erectile dysfunction and a study of 32 elderly patients with polymorbidity. These studies reported some beneficial effects but also identified concerning signals including prooxidant activity and reduced blood stem cell counts in one study. None of these studies used a placebo control group, and no large randomized controlled trials have been conducted. Vesugen is not approved for human therapeutic use anywhere.

How does Vesugen differ from other peptide bioregulators?

Vesugen is specifically associated with vascular and endothelial biology within the Khavinson peptide bioregulator family, which includes compounds targeting other organ systems such as the pineal gland (Epithalon), the brain (Pinealon), and the thymus (Thymalin). Its proposed mechanism of directly binding to a specific gene promoter region to influence gene transcription is described as a distinguishing feature, though this mechanism has not been independently replicated outside the originating laboratory.

References

1. Khavinson, V.K., Linkova, N.S., Kvetnoy, I.M., & Polyakova, V.O. (2011). Epigenetic aspects of vascular wall aging. Advances in Gerontology, 24(3), 388-398. PubMed

2. Khavinson, V., Linkova, N., Kozhevnikova, E., & Trofimova, S. (2022). EDG peptide epigenetic aspects of vascular wall protection in aging. Molecules, 27(2), 444. PubMed

3. Khavinson, V.K., Tarnovskaya, S.I., Linkova, N.S., Pronyaeva, V.E., Shataeva, L.K., & Yakutseni, P.P. (2013). Short peptides and their role in regulation of gene expression. Bulletin of Experimental Biology and Medicine, 154(5), 694-698. PubMed

4. Linkova, N.S., Khavinson, V.K., Kvetnoy, I.M., Paltsev, M.A., & Polyakova, V.O. (2012). Peptide regulation of cell differentiation, aging and proliferation. Advances in Gerontology, 25(3), 394-403. PubMed

5. Khavinson, V.K., Linkova, N.S., Tarnovskaya, S.I., & Elashkina, E.V. (2014). Molecular mechanism of vasotropic activity of the KED tripeptide. Bulletin of Experimental Biology and Medicine, 157(4), 509-511. PubMed

6. Khavinson, V.K., Linkova, N.S., Dudkov, A.V., Orlova, A.A., & Nichik, T.E. (2011). Peptidergic regulation of genes encoding vascular protective functions. Bulletin of Experimental Biology and Medicine, 151(4), 448-452. PubMed

7. Linkova, N.S., Khavinson, V.K., Kuznik, B.I., & Tarnovskaya, S.I. (2016). Short bioregulatory peptides: age-associated changes of gene expression and protein synthesis. Advances in Gerontology, 29(5), 757-767. PubMed

8. Grigorev, I.P., Sukhorukova, E.G., Tsybulskaya, E.A., Kovalenko, N.A., Linkova, N.S., & Khavinson, V.K. (2016). Neuroprotective effect of KED peptide on amyloid-induced synaptotoxicity. Advances in Gerontology, 29(4), 541-548. PubMed

9. Sukhorukova, E.G., Grigorev, I.P., Kovalenko, N.A., Tsybulskaya, E.A., Linkova, N.S., Khavinson, V.K., & Kvetnoy, I.M. (2017). Effects of peptides KED and AEDG on dendritic spine density of neurons in models of Huntington’s disease and amyloid synaptotoxicity. Advances in Gerontology, 30(2), 211-218. PubMed

10. Linkova, N.S., Khavinson, V.K., Yakhno, N.N., & Sugonyaeva, N.P. (2015). Peptide KED stimulation of neuronal differentiation of human dental pulp stem cells. Bulletin of Experimental Biology and Medicine, 158(6), 818-821. PubMed

11. Kuznik, B.I., Linkova, N.S., Khavinson, V.K., Ryzhak, A.P., & Ryzhak, G.A. (2013). Peptide bioregulators for treatment and prevention of age-related vascular pathology. Advances in Gerontology, 26(1), 89-97. PubMed

12. Grigorev, I.P., Kovalenko, N.A., Linkova, N.S., Ryzhak, G.A., & Khavinson, V.K. (2014). Correction of cerebral ischemia in aged animals by KED peptide. Advances in Gerontology, 27(3), 464-468. PubMed

13. Kuznik, B.I., Ryzhak, G.A., Chepelev, V.V., Linkova, N.S., & Khavinson, V.K. (2012). Effect of Vesugen and Pinealon on indicators of biological age in elderly patients with polymorbidity. Advances in Gerontology, 25(2), 310-318. PubMed

14. Khavinson, V.K., Linkova, N.S., Dudkov, A.V., & Polyakova, V.O. (2012). Peptides stimulate expression of proteins that perform vasoprotective functions. Bulletin of Experimental Biology and Medicine, 152(6), 750-752. PubMed

15. Khavinson, V., Diomede, F., Mironova, E., Linkova, N., Trofimova, S., Trubiani, O., Caputi, S., & Sinjari, B. (2020). AEDG peptide (Epitalon) stimulates gene expression and differentiation of stem cells. International Journal of Molecular Sciences, 21(16), 5562. PubMed

16. Linkova, N.S., Khavinson, V.K., Ivanova, D.V., Kolchina, N.V., Golovkin, V.M., & Kvetnoj, I.M. (2021). Peptide bioregulation of aging-associated vascular pathological processes. Advances in Gerontology, 34(2), 240-249. PubMed

17. Khavinson, V.K., Tarnovskaya, S.I., Linkova, N.S., Kvetnoy, I.M., & Polyakova, V.O. (2016). Short signal peptides mediate gene expression via chromatin. Archives of Gerontology and Geriatrics, 64, 240-249. PubMed